| Literature DB >> 30845182 |
Abstract
Inthe present study, we have demonstrated the phytochemical composition of petroleum ether extract of C. sativum (CPE) seeds by using chromatographic, spectroscopic as well spectrometric analysis. CPE was evaluated for its possible role in mitigation of diabetic nephropathy (DN) in Streptozotocin (STZ)-nicotinamide (NAD) induced type 2 diabetes model. Administration of CPE at doses of 100, 200, and 400 mg/kg for 45 days has produced significant attenuation of elevated biochemical parameters including serum glucose, lipid and creatinine levels. CPE has also reserved albuminuria and elevated creatinine clearance in treated diabetic rats. Advanced glycation end products (AGEs) formation in kidneyswas also considerably reduced along with noteworthy increase in level of superoxide dismutase (SOD), glutathione (GSH), and decrease in lipid peroxidation in terms of thiobarbituric acid reactive species (TBARS). Molecular docking studies were also employed to reveal out the possible mechanism. In conclusion, using STZ-NAD model, we have successfully predicted that by assets of bioactive constituents CPE might inhibit the progression of DN. C. sativum may act as potential adjuvant for antidiabetic therapy and needs to be investigated further.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30845182 PMCID: PMC6405108 DOI: 10.1371/journal.pone.0213147
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
GC-MS analysis result of C. sativum petroleum ether extract (CPE).
| Peak | Retention time | Area % | Database/NIST 14 library |
|---|---|---|---|
| 1 | 7.87 | 2.39 | Linalool |
| 2 | 18.64 | 11.53 | Ascorbyl Palmitate |
| 3 | 20.40 | 69.38 | Petroselinic acid |
| 4 | 20.53 | 2.22 | Docosahexanoic acid |
| 5 | 22.08 | 2.56 | Linoleic acid |
| 6 | 23.62 | 1.62 | α-Linolenic acid |
| 7 | 24.95 | 10.30 | Oleic acid |
Effect of C. sativum petroleum ether extract (CPE) on biochemical parameters in diabetic nephropathy rats.
| Groups | Normal control | DN control | CPE 100 mg/kg | CPE 200 mg/kg | CPE 400 mg/kg | Glimepiride 10 mg/kg |
|---|---|---|---|---|---|---|
| TC (mg/dL) | 102.33 ± 2.04 | 299.55 ± 2.10 a* | 215.12 ± 0.82 b* | 179.03 ± 1.42 b*c* | 159.65 ± 2.02b*c*d* | 151.83 ± 2.19b* |
| LDL (mg/dL) | 36.50 ± 1.64 | 233.38 ± 2.21 a* | 133.25 ± 1.27b* | 110.87 ± 1.19b*c# | 90.43 ± 1.78b*c*d* | 94.90 ± 1.59b* |
| TG (mg/dL) | 73.67 ± 1.41 | 205.80 ± 1.61a* | 128.78 ± 1.35b* | 117.49 ± 0.82b*c# | 106.24 ± 0.89b*c*d# | 100.13 ± 1.92b* |
| HDL (mg/dL) | 57.50 ± 0.96 | 27.44 ± 0.77a* | 36.45 ± 0.76 b* | 40.36 ± 0.29b*c† | 45.71 ± 0.36b*c*d# | 36.17 ± 0.80b* |
| AST (IU/L) | 37.01± 1.21 | 84.75± 2.58 a* | 70.15± 1.33 b* | 58.33± | 46.23± | 45.39± 1.09 b* |
| ALT | 29.41± | 72.02± | 66.28± | 56.38± | 39.09± | 36.98±1.43 b* |
| Urea (mg/dL) | 34.73 ± 0.95 | 89.33 ± 1.41 a* | 58.39 ± 0.78b* | 52.13 ± 1.30b*c* | 48.52 ± 1.18b*c*d† | 55.50 ± 1.26b* |
| Uric acid (mg/dL) | 5.07 ± 0.13 | 15.10 ± 0.38 a* | 8.39 ± 0.12b* | 7.97 ± 0.16b* | 7.36 ± 0.25b*c#d† | 7.67 ± 0.18b* |
| Creatinine (mg/dL) | 0.70 ± 0.11 | 3.92 ± 0.03 a* | 2.96 ±0.07b* | 2.56 ± 0.03b*c† | 2.16 ± 0.05b*c*d* | 1.56 ± 0.07b* |
| BUN (mg/dL) | 16.73 ± 0.44 | 41.72 ± 0.66b* | 23.93 ± 0.36b*c* | 21.61 ± 0.61b*c# | 18.32 ± 0.49b*c*d† | 25.92 ± 0.59b* |
| UAE (μg/24 hrs) | 210.66 ± 0.32 | 1548.25 ± 0.90a* | 491.23 ± 7.28b* | 465.67 ± 4.02b*c# | 452.09 ± 7.39b*c#d* | 489.24 ± 9.04b* |
| Creatinine clearance | 3.09 ± 0.07 | 3.75 ± 0.18 | 3.80 ± 0.18 b# | 5.23 ± 0.24 b* | 8.24 ± 0.58b*c*d# | 8.93 ± 0.39b* |
| SOD (U/mg protein) | 3.67 ± 0.08 | 1.23 ± 0.03 a* | 1.69 ± 0.03b* | 2.19 ± 0.02b*c* | 3.17 ± 0.06b*c*d* | 3.41 ± 0.03b* |
| GSH (μM/mg protein) | 69.04 ± 0.47 | 36.07 ± 0.44 a* | 40.01 ± 0.51b* | 48.99 ± 0.35b*c* | 56.37 ± 0.39b*c*d* | 60.51 ± 0.49b* |
| TBARS (nmol/mg protein) | 0.57 ± 0.02 | 2.29 ± 0.03a* | 2.11 ± 0.01b* | 1.91 ± 0.03b*c† | 1.60 ± 0.02b*c* | 1.69 ± 0.03b* |
| AGEs | 1.62± | 3.78± | 3.24± | 2.80± | 2.64± | 3.50± |
Values are expressed as mean ± S.E.M. (n = 6 in each group).